IGC Financials

Income Statement
MetricQ2 2026Q1 2026Q2 2025Q1 2025Q4 2025
Revenue
265.0K
-16.4%
317.0K
-3.4%
328.0K
-0.6%
330.0K
+0.0%
330.0K
Cost of Revenue
217.0K
-17.2%
262.0K
+50.6%
174.0K
-1.1%
176.0K
+0.0%
176.0K
Gross Profit
48.0K
-12.7%
55.0K
-64.3%
154.0K
+0.0%
154.0K
+0.0%
154.0K
Operating Expenses
2.8M
+12.7%
2.5M
+22.0%
2.1M
+31.4%
1.6M
+0.1%
1.6M
R&D
1.4M
+9.3%
1.3M
+49.5%
851.0K
-14.6%
997.0K
+0.0%
997.0K
SG&A
1.4M
+16.2%
1.2M
+2.7%
1.2M
+111.9%
570.0K
+0.2%
569.0K
Operating Income
-2784000
-13.3%
-2458000
-29.0%
-1905000
-34.8%
-1413000
-0.1%
-1412000
EBITDA
-2728000
-13.7%
-2400000
-36.1%
-1764000
-40.1%
-1259000
+1.9%
-1283000
Net Income
-2936000
-22.2%
-2402000
-50.2%
-1599000
-33.5%
-1198000
-0.1%
-1197000
EPS (Basic)
$-0.03
-50.0%
$-0.02
+0.0%
$-0.02
+0.0%
$-0.02
+0.0%
$-0.02
EPS (Diluted)
$-0.03
-50.0%
$-0.02
+0.0%
$-0.02
+0.0%
$-0.02
+0.0%
$-0.02
Shares (Diluted)
100.3M
+2.2%
98.2M
+18.2%
83.0M
+4.2%
79.7M
+21.2%
65.8M
IGC Pharma (IGC) โ€” Financials